Insmed (INSM) Receiving Somewhat Favorable Press Coverage, Accern Reports

Media coverage about Insmed (NASDAQ:INSM) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insmed earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.2755911440849 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media headlines that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

Shares of Insmed stock opened at $20.06 on Monday. The company has a market cap of $1,537.06, a P/E ratio of -6.94 and a beta of 1.11. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.72 and a current ratio of 8.72. Insmed has a 1 year low of $11.49 and a 1 year high of $33.94.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). equities research analysts forecast that Insmed will post -3.8 EPS for the current year.

Several equities analysts have commented on the stock. Robert W. Baird reissued a “positive” rating and issued a $42.00 target price (up from $32.00) on shares of Insmed in a report on Thursday, January 4th. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Insmed in a report on Thursday, January 4th. Zacks Investment Research lowered shares of Insmed from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub raised shares of Insmed from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, Credit Suisse Group assumed coverage on shares of Insmed in a report on Wednesday, January 17th. They issued a “neutral” rating and a $31.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $36.90.

COPYRIGHT VIOLATION WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3343285/insmed-insm-receiving-somewhat-favorable-press-coverage-accern-reports.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Cubits  Trading 3.7% Lower  This Week
Cubits Trading 3.7% Lower This Week
Peculium  Trading 14.2% Higher  Over Last Week
Peculium Trading 14.2% Higher Over Last Week
Lakeland Industries  Stock Rating Upgraded by Zacks Investment Research
Lakeland Industries Stock Rating Upgraded by Zacks Investment Research
Cornerstone OnDemand  Price Target Raised to $52.00
Cornerstone OnDemand Price Target Raised to $52.00
Ctrip’s  Buy Rating Reaffirmed at Barclays
Ctrip’s Buy Rating Reaffirmed at Barclays
Barclays Cuts Fulton Financial  Price Target to $18.00
Barclays Cuts Fulton Financial Price Target to $18.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.